newsfilter
← Latest News
Business Wire·

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KarXT for the treatment of schizophrenia in the third quarter of 2023 Initiated the Phase 3 ADEPT-2 and ADEPT-3 trials evaluating